{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T04:34:20Z","timestamp":1776918860585,"version":"3.51.2"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2022R1A2C2004933"],"award-info":[{"award-number":["NRF-2022R1A2C2004933"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013521","name":"Cosmetic Surgery Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013521","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.ejmech.2022.114837","type":"journal-article","created":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T07:01:06Z","timestamp":1665558066000},"page":"114837","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Discovery of potent indazole-based human glutaminyl cyclase (QC) inhibitors as Anti-Alzheimer's disease agents"],"prefix":"10.1016","volume":"244","author":[{"given":"Nguyen","family":"Van Manh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Van-Hai","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Van T.H.","family":"Ngo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soosung","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Ju","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hee-Jin","family":"Ha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Ho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jihyae","family":"Ann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7832-6719","authenticated-orcid":false,"given":"Jeewoo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2022.114837_bib1","article-title":"Alzheimer's disease drug development pipeline: 2022","volume":"8","author":"Cummings","year":"2022","journal-title":"Transl. Res. & Clin. Interv."},{"key":"10.1016\/j.ejmech.2022.114837_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114578","article-title":"Molecular mechanisms in Alzheimer's disease and related potential treatments such as structural target convergence of antibodies and simple organic molecules","volume":"240","author":"Oumata","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114837_bib3","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.drudis.2022.01.016","article-title":"Challenges and hopes for alzheimer's disease","volume":"27","author":"Tatulian","year":"2022","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2022.114837_bib4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s13311-022-01201-2","article-title":"Disease-modifying therapies for Alzheimer's disease: more questions than answers","volume":"19","author":"Golde","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ejmech.2022.114837_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120861","article-title":"Alzheimer's disease failed clinical trials","volume":"306","author":"Asher","year":"2022","journal-title":"Life Sci."},{"key":"10.1016\/j.ejmech.2022.114837_bib6","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3233\/JAD-215699","article-title":"Alzheimer's disease: key insights from two decades of clinical trial failures","volume":"87","author":"Kim","year":"2022","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.ejmech.2022.114837_bib7","doi-asserted-by":"crossref","first-page":"38825","DOI":"10.1074\/jbc.R111.288308","article-title":"Pyroglutamate amyloid-beta (A-beta): a hatchet man in alzheimer's disease","volume":"286","author":"Jawhar","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2022.114837_bib8","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/0896-6273(95)90301-1","article-title":"Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques","volume":"14","author":"Saido","year":"1995","journal-title":"Neuron"},{"key":"10.1016\/j.ejmech.2022.114837_bib9","doi-asserted-by":"crossref","first-page":"7072","DOI":"10.1021\/bi900818a","article-title":"Pyroglutamate formation influences solubility and amyloidogenicity of amyloid peptides","volume":"48","author":"Schlenzig","year":"2009","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2022.114837_bib10","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3233\/JAD-131535","article-title":"Glutaminyl cyclase in human cortex: correlation with (pGlu)-amyloid-beta load and cognitive decline in alzheimer's disease","volume":"39","author":"Morawski","year":"2014","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.ejmech.2022.114837_bib11","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1046\/j.1471-4159.2002.01107.x","article-title":"Pyroglutamate-modified amyloid beta-peptides-AbetaN3(pE)-strongly affect cultured neuron and astrocyte survival","volume":"82","author":"Russo","year":"2002","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejmech.2022.114837_bib12","doi-asserted-by":"crossref","first-page":"10871","DOI":"10.1021\/bi990563r","article-title":"The A beta 3-pyroglutamyl and 11-pyroglutamyl peptides found in senile plaque have greater beta-sheet forming and aggregation propensities in vitro than full-length A beta","volume":"38","author":"He","year":"1999","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2022.114837_bib13","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nature11060","article-title":"Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-beta","volume":"485","author":"Nussbaum","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.114837_bib15","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s00401-014-1287-x","article-title":"Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer's disease","volume":"127","author":"Bayer","year":"2014","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.ejmech.2022.114837_bib16","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1073\/pnas.84.11.3628","article-title":"Identification of a mammalian glutaminyl cyclase converting glutaminyl into pyroglutamyl peptides","volume":"84","author":"Fischer","year":"1987","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2022.114837_bib17","doi-asserted-by":"crossref","first-page":"8532","DOI":"10.1016\/S0021-9258(18)47446-7","article-title":"An enzyme(s) that converts glutaminyl-peptides into pyroglutamyl-peptides. Presence in pituitary, brain, adrenal medulla, and lymphocytes","volume":"262","author":"Busby","year":"1987","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2022.114837_bib18","doi-asserted-by":"crossref","first-page":"10059","DOI":"10.1073\/pnas.88.22.10059","article-title":"Primary structure and functional expression of a glutaminyl cyclase","volume":"88","author":"Pohl","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2022.114837_bib19","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3233\/JAD-131535","article-title":"Glutaminyl cyclase in human cortex: correlation with (pGlu)-amyloid-beta load and cognitive decline in alzheimer's disease","volume":"39","author":"Morawski","year":"2014","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.ejmech.2022.114837_bib20","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/jnc.15114","article-title":"Increased glutaminyl cyclase activity in brains of alzheimer's disease individuals","volume":"156","author":"Gunn","year":"2021","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejmech.2022.114837_bib21","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1074\/jbc.M110.185819","article-title":"Overexpression of glutaminyl cyclase, the enzyme responsible for pyroglutamate A-beta formation, induces behavioral deficits, and glutaminyl cyclase knock-out rescues the behavioral phenotype in 5XFAD mice","volume":"286","author":"Jawhar","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2022.114837_bib22","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/nm.1872","article-title":"Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and alzheimer's disease-like pathology","volume":"14","author":"Schilling","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2022.114837_bib23","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1111\/j.1471-4159.2008.05471.x","article-title":"Inhibition of glutaminyl cyclase prevents pGlu-Abeta formation after intracortical\/hippocampal microinjection in vivo\/in situ","volume":"106","author":"Schilling","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejmech.2022.114837_bib24","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1586\/14737175.2015.1088784","article-title":"Hypothesis: glutaminyl cyclase inhibitors decrease risks of alzheimer's disease and related dementias","volume":"15","author":"Hennekens","year":"2015","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.ejmech.2022.114837_bib25","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.4155\/fmc-2017-0190","article-title":"Can small molecule inhibitors of glutaminyl cyclase be used as a therapeutic for alzheimer's disease","volume":"9","author":"Wu","year":"2017","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114837_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104342","article-title":"Human glutaminyl cyclase: structure, function, inhibitors and involvement in alzheimer's disease","volume":"147","author":"Vijayan","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2022.114837_bib27","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.4155\/fmc-2019-0163","article-title":"An overview of glutaminyl cyclase inhibitors for alzheimer's disease","volume":"11","author":"Coimbra","year":"2019","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114837_bib28","doi-asserted-by":"crossref","first-page":"6549","DOI":"10.1021\/acs.jmedchem.1c00325","article-title":"Glutaminyl cyclase, diseases, and development of glutaminyl cyclase inhibitors","volume":"64","author":"Xu","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114837_bib29","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1080\/13543776.2021.1917549","article-title":"A patent review of glutaminyl cyclase inhibitor (2004-present)","volume":"31","author":"Coimbra","year":"2021","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2022.114837_bib30","doi-asserted-by":"crossref","DOI":"10.1021\/jm050756e","article-title":"The first potent inhibitors for human glutaminyl cyclase: synthesis and structure-activity relationship","volume":"49","author":"Buchholz","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114837_bib31","doi-asserted-by":"crossref","first-page":"7069","DOI":"10.1021\/jm900969p","article-title":"Inhibitors for human glutaminyl cyclase by structure based design and bioisosteric replacement","volume":"52","author":"Buchholz","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114837_bib32","doi-asserted-by":"crossref","first-page":"6613","DOI":"10.1021\/jm4001709","article-title":"Structure-activity relationships of benzimidazole-based glutaminyl cyclase inhibitors featuring a heteroaryl scaffold","volume":"56","author":"Ramsbeck","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114837_bib33","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1124\/jpet.117.240614","article-title":"Glutaminyl cyclase inhibitor PQ912 improves cognition in mouse models of alzheimer's disease-studies on relation to effective target occupancy","volume":"362","author":"Hoffmann","year":"2017","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2022.114837_bib35","first-page":"182","article-title":"A phase 1 study to evaluate the safety and pharmacokinetics of PQ912, a glutaminyl cyclase inhibitor, in healthy subjects","volume":"1","author":"Lues","year":"2015","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.ejmech.2022.114837_bib36","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13195-018-0431-6","article-title":"Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor of PQ912 in alzheimer's disease: result of a randomized, double-blind, placebo-controlled phase 2a study","volume":"10","author":"Scheltens","year":"2018","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.ejmech.2022.114837_bib37","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.clinph.2019.09.014","article-title":"In pursuit of a sensitive EEG functional connectivity outcome measure for clinical trials in alzheimer's disease","volume":"131","author":"Briels","year":"2020","journal-title":"Clin. Neurophysiol."},{"key":"10.1016\/j.ejmech.2022.114837_bib38","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s13195-021-00882-9","article-title":"Rationale and study design of a randomized, placebo-controlled, double-blind phase 2b trial to evaluate efficacy, safety, and tolerability of an oral glutaminyl cyclase inhibitor varoglutamstat (PQ912) in study participants with MCI and mild AD-VIVIAD","volume":"13","author":"Vijverberg","year":"2021","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.ejmech.2022.114837_bib39","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/cbdd.13940","article-title":"Exploring the binding mode of PQ912 against secretory glutaminyl cyclase through systematic exploitation of conformational ensembles","volume":"98","author":"Chandran","year":"2021","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2022.114837_bib40","doi-asserted-by":"crossref","first-page":"6664","DOI":"10.1021\/acs.jmedchem.7b00648","article-title":"Synthesis and evaluation of diphenyl conjugated imidazole derivatives as potential glutaminyl cyclase inhibitors for treatment of alzheimer's disease","volume":"60","author":"Li","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114837_bib41","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nchembio.1790","article-title":"siRNAscreen identifies QPCT as a druggable target for huntington's disease","volume":"11","author":"Jimenez-Sanchez","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114837_bib42","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s00775-018-1605-1","article-title":"The structure of the human glutaminyl cyclase-SEN177 complex indicates routes for developing new potent inhibitors as possible agents for the treatment of neurological disorders","volume":"23","author":"Pozzi","year":"2018","journal-title":"J. Biol. Inorg. Chem."},{"key":"10.1016\/j.ejmech.2022.114837_bib43","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3390\/md14110203","article-title":"Natural products from microalgae with potential against alzheimer's disease: sulfolipids are potent glutaminyl cyclase inhibitors","volume":"14","author":"Hielscher-Michael","year":"2016","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.ejmech.2022.114837_bib44","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/j.bmc.2016.03.064","article-title":"Inhibitory effect of flavonoids on human glutaminyl cyclase","volume":"24","author":"Li","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114837_bib45","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s11030-016-9717-4","article-title":"Identification of potential glutaminyl cyclase inhibitors from lead-like libraries by in silico and in vitro fragment-based screening","volume":"21","author":"Szaszk\u00f3","year":"2017","journal-title":"Mol. Divers."},{"key":"10.1016\/j.ejmech.2022.114837_bib46","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s12010-018-2780-9","article-title":"Identifying hQC inhibitors of alzheimer's disease by effective customized pharmacophore-based virtual screening, molecular dynamic simulation, and binding free energy analysis","volume":"187","author":"Lin","year":"2019","journal-title":"Appl. Biochem. Biotechnol."},{"key":"10.1016\/j.ejmech.2022.114837_bib47","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1021\/acs.biochem.0c00337","article-title":"Hydrazides are potent transition-state analogues for glutaminyl cyclase implicated in the pathogenesis of alzheimer's disease","volume":"59","author":"Kupski","year":"2020","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2022.114837_bib48","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.3390\/ph14121206","article-title":"Tetrahydroimidazo[4,5-c]pyridine-based inhibitors of porphyromonas gingivalis glutaminyl cyclase","volume":"14","author":"Ramsbeck","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2022.114837_bib49","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ijbiomac.2020.12.118","article-title":"Piperidine-4-carboxamide as a new scaffold for designing secretory glutaminyl cyclase inhibitors","volume":"170","author":"Dileep","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejmech.2022.114837_bib50","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1016\/j.bmc.2013.04.005","article-title":"Structure\u2013activity relationship of human glutaminyl cyclase inhibitors having an N-(5-methyl-1H-imidazole-1-yl)propyl thiourea template","volume":"21","author":"Tran","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114837_bib51","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1021\/acs.jmedchem.7b00098","article-title":"Discovery of potent human glutaminyl cyclase inhibitors as anti-alzheimer\u2019s agents based on rational design","volume":"60","author":"Hoang","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114837_bib52","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.bmc.2018.01.015","article-title":"Potent human glutaminyl cyclase inhibitors as potential anti-alzheimer\u2019s agents: structure-activity relationship study of Arg-mimetic region","volume":"26","author":"Ngo","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114837_bib53","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1016\/j.bmc.2018.04.040","article-title":"Structure-activity relationship investigation of Phe-Arg mimetic region of human glutaminyl cyclase inhibitors","volume":"26","author":"Ngo","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114837_bib54","doi-asserted-by":"crossref","first-page":"8011","DOI":"10.1021\/acs.jmedchem.9b00751","article-title":"Discovery of conformationally restricted human glutaminyl cyclase inhibitors as potent anti-alzheimer\u2019s agents by structure-based design","volume":"62","author":"Hoang","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114837_bib55","article-title":"Discovery of highly potent human glutaminyl cyclase (QC) inhibitors as anti-Alzheimer's agents by the combination of pharmacophorebased and structure-based design","volume":"226","author":"Manh","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114837_bib56","doi-asserted-by":"crossref","first-page":"8827","DOI":"10.1021\/jm301119s","article-title":"Pharmacokinetic benefits of 3,4-dimethoxy substitution of a phenyl ring and design of isosteres yielding orally available cathepsin K inhibitors","volume":"55","author":"Crawford","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114837_bib57","unstructured":"W-L. Wu, D. A. Burnett, A. Stamford, J. N. Cumming, T. Asberom, C. Bennett, T. K. Sasiskumar, J. D. Scott, 2-Spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use. WO Patent WO 2013 028670 A1."},{"key":"10.1016\/j.ejmech.2022.114837_bib58","unstructured":"F. C. Cordobes, C. Alansarosales, E. M. A. Galcera, M. T. S. Cabanes, M. G. Lopez, Piperidine compounds having multimodal activity against pain. WO Patent WO 2015 091988 A1."},{"key":"10.1016\/j.ejmech.2022.114837_bib59","doi-asserted-by":"crossref","first-page":"6373","DOI":"10.1016\/0040-4039(95)01316-A","article-title":"2- and 4-Nitrobenzenesulfonamides: exceptionally versatile means for preparation of secondary amines and protection of amines","volume":"36","author":"Fukuyama","year":"1995","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.ejmech.2022.114837_bib60","article-title":"Preparation of secondary amines from primary amines via 2\u2010nitrobenzenesulfonamides: N\u2010(4\u2010methoxybenzyl)\u20103\u2010phenylpropylamine","volume":"79","author":"Kurosawa","year":"2003","journal-title":"Org. Synth."},{"key":"10.1016\/j.ejmech.2022.114837_bib61","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1006\/abio.2001.5560","article-title":"Continuous spectrometric assays for glutaminyl cyclase activity","volume":"303","author":"Schilling","year":"2002","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ejmech.2022.114837_bib62","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1021\/jm060230+","article-title":"Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability","volume":"49","author":"Ottaviani","year":"2006","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422007395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422007395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:50:16Z","timestamp":1759330216000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523422007395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":60,"alternative-id":["S0223523422007395"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114837","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of potent indazole-based human glutaminyl cyclase (QC) inhibitors as Anti-Alzheimer's disease agents","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114837","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114837"}}